Investors: Press Releases

Press Releases

April 21, 2021
NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs
March 31, 2021
NexImmune Reports Fiscal Year 2020 Financial Results and Recent Updates
March 2, 2021
NexImmune to Present at the 2021 Barclays Global Healthcare Conference
February 17, 2021
NexImmune Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 11, 2021
NexImmune Announces Pricing of Upsized Initial Public Offering
January 19, 2021
NexImmune Appoints Healthcare Innovator Grant Verstandig as New Board Member
January 18, 2021
Immunotherapy Veteran Robert Knight, MD, Joins NexImmune as Chief Medical Officer
January 4, 2021
NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&D and Jeffrey Weber as Chief Scientific Advisor
December 7, 2020
Preliminary Results from NexImmune’s Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition
November 4, 2020
NexImmune to Highlight Preliminary Results from Phase 1/2 Trial of NEXI-001 via Oral Presentation at 62nd ASH Annual Meeting
Displaying 11 - 20 of 37